NH Nongwoobio Co., Ltd. (KOSDAQ:054050)
8,160.00
+40.00 (0.49%)
At close: Apr 29, 2026
NH Nongwoobio Revenue
In the year 2025, NH Nongwoobio had annual revenue of 158.79B KRW with 9.75% growth. NH Nongwoobio had revenue of 39.18B in the quarter ending December 31, 2025, with 24.68% growth.
Revenue
158.79B
Revenue Growth
+9.75%
P/S Ratio
0.82
Revenue / Employee
476.84M
Employees
333
Market Cap
129.53B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 158.79B | 14.11B | 9.75% |
| Dec 31, 2024 | 144.68B | 8.84B | 6.50% |
| Dec 31, 2023 | 135.84B | 2.44B | 1.83% |
| Dec 31, 2022 | 133.40B | 557.04M | 0.42% |
| Dec 31, 2021 | 132.84B | 2.81B | 2.16% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| XEXYMIX | 274.10B |
| Pungguk Ethanol | 163.52B |
| HYUNDAI BIOLAND | 130.51B |
| Daejoo | 100.98B |
| KOREA PHARMA | 87.60B |
| meerecompany | 40.90B |
| BIOBIJOU | 28.49B |
| Cytogen | 26.05B |